You’re reading the web edition of DC Diagnosis, STAT’s twice-weekly health and healthcare politics and policy newsletter. Sign up here to receive the newsletter delivered to your inbox on Tuesdays and Thursdays.
A good deal or not?
The deadline for Medicare to announce its first drug price negotiations is fast approaching, and if you’re wondering how to tell if the Biden administration has made a hard bargain, my colleague John Wilkerson has some tips.
Determining negotiated prices is not easy, but there are at least four ways: Are you saving taxpayers’ money? Are you saving seniors’ money? Are you priced appropriately for the value provided? Are you still paying more than other countries?
This article is exclusive to STAT+ subscribers
By unlocking this article, you will also get access to in-depth analysis, our newsletter, premium events and our networking platform.
Already have an account? Log in
Already have an account? Log in
See all plans
Get unlimited access to award-winning journalism and exclusive events.
subscribe
